Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studies.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Seminars in hematology (Print)

• Publication date

  2012-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1053/j.seminhematol.2012.04.006PMID 22726545PMCID PMC3383768
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PR‐924, a selective inhibitor of the immunoproteasome subunit LMP‐7, blocks multiple myeloma cell growth both in vitro and in vivo

  2011cited by this paper
• Polyubiquitin Linkage Profiles in Three Models of Proteolytic Stress Suggest the Etiology of Alzheimer Disease*

  2011cited by this paper
• Carfilzomib-Dependent Selective Inhibition of the Chymotrypsin-like Activity of the Proteasome Leads to Antitumor Activity in Waldenstrom's Macroglobulinemia

  2011cited by this paper
• Proteasome inhibition can induce an autophagy-dependent apical activation of caspase-8

  2011cited by this paper
• In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells

  2011cited by this paper
• Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma

  2011cited by this paper
• Targeting IRE1α-XBP1 Pathway Is a Novel Therapeutic Strategy In Multiple Myeloma

  2010cited by this paper
• CBL Mutations In Pediatric Acute Myelogenous Leukemia Are a Rare Event, a Report From the Children's Oncology Group.

  2010cited by this paper
• Quantitative proteomics reveals the function of unconventional ubiquitin chains in proteasomal degradation.

  2009cited by this paper
• Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.

  2009cited by this paper
• Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.

  2009cited by this paper
• Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications.

  2009cited by this paper
• Impact of XIAP protein levels on the survival of myeloma cells

  2009cited by this paper
• Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells

  2008cited by this paper
• Bortezomib-Resistant Nuclear Factor-κB Activity in Multiple Myeloma Cells

  2008cited by this paper
• Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.

  2007cited by this paper
• Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

  2007cited by this paper
• Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications.

  2007cited by this paper
• Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.

  2007cited by this paper
• Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

  2007cited by this paper
• Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.

  2006cited by this paper
• MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.

  2006cited by this paper
• MLN120B, a Novel IκB Kinase β Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo

  2006cited by this paper
• Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.

  2005cited by this paper
• Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines.

  2005cited by this paper
• Intracellular Protein Degradation and Its Therapeutic Implications

  2005cited by this paper
• Targeting proteasome inhibition in hematologic malignancies.

  2003cited by this paper
• Inhibition of proteasome‐dependent degradation of Wee1 in G2‐arrested Hep3B cells by TGFβ1

  2003cited by this paper
• Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

  2003cited by this paper
• Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

  2003cited by this paper
• NF-κB as a Therapeutic Target in Multiple Myeloma*

  2002cited by this paper
• NF-kappa B as a therapeutic target in multiple myeloma.

  2002cited by this paper
• The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

  2001cited by this paper
• Proteasome inhibitors: from research tools to drug candidates.

  2001cited by this paper
• The I kappa B proteins: multifunctional regulators of Rel/NF-kappa B transcription factors.

  1993cited by this paper

• Exploration of genes related to the development of cancer of unknown primary

  2025cites this paper
• Mechanism regulation of endoplasmic reticulum stress in multiple myeloma cells: modulation of the UPR, UPS, autophagy, HSPs, and potential therapeutic targets

  2025cites this paper
• Insights into the protein domains of C-VI TRIM subfamily in viral infection

  2025cites this paper
• Interplay between proteasome inhibitors and NF-κB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors

  2024cites this paper
• Advancements in drugs restructured with nanomedicines for multiple myeloma treatment

  2024cites this paper
• Recent advances and future perspectives of noncompetitive proteasome inhibitors.

  2023cites this paper
• Indirubin-3’-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma

  2022cites this paper
• RARγ activation sensitizes human myeloma cells to carfilzomib treatment through OAS-RNase L innate immune pathway.

  2021cites this paper
• Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network

  2021cites this paper
• 3D Models of Surrogate Multiple Myeloma Bone Marrow Microenvironments: Insights on Disease Pathophysiology and Patient-Specific Response to Drugs

  2021cites this paper
• Multiple myeloma cells are exceptionally sensitive to heat shock, which overwhelms their proteostasis network and induces apoptosis

  2020cites this paper
• Multiple myeloma: the (r)evolution of current therapy and a glance into future.

  2020cites this paper
• MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma.

  2020cites this paper
• Identification of berberine as a novel drug for the treatment of multiple myeloma via targeting UHRF1

  2020cites this paper
• New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm.

  2020cites this paper
• Multiple myeloma: the (r)evolution of current therapy and a glance into future.

  2020cites this paper
• Old and new generation proteasome inhibitors in multiple myeloma.

  2020cites this paper
• Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma

  2019cites this paper
• Enhanced Dendritic Cell Development Through Long-Term Proteasome Inhibition

  2018cites this paper
• Nanotherapeutics for multiple myeloma.

  2018cites this paper
• The power of proteasome inhibition in multiple myeloma

  2018cites this paper
• The safety of bortezomib for the treatment of multiple myeloma

  2018cites this paper
• The proteasome and proteasome inhibitors in multiple myeloma

  2017cites this paper
• Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis

  2017cites this paper
• Immunomodulatory Agents and Proteasome Inhibitors in the Treatment of Multiple Myeloma.

  2017cites this paper
• Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.

  2016cites this paper
• Novel therapeutic strategies for multiple myeloma.

  2015cites this paper
• A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells

  2015cites this paper
• Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma.

  2015cites this paper
• When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response

  2015cites this paper
• Autophagy, a new determinant of plasma cell differentiation and antibody responses.

  2014cites this paper
• HO-1 up-regulation: a key point in high-risk neuroblastoma resistance to bortezomib.

  2014cites this paper
• The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma

  2014cites this paper
• Carfilzomib in multiple myeloma

  2014cites this paper
• Autophagy in Plasma Cell Pathophysiology

  2014cites this paper
• Synthetic lethal genetic screens in Ras mutant cancers.

  2013cites this paper
• Downregulation of PA28 alpha induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma

  year unknowncites this paper